EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world effectiveness of inactivated vaccine on COVID-19 patients with comorbidities

Hao Zhang, Hua-Fang Yan, Wu-Jun Xiong, Li-Li Gao

The Journal of Infection in Developing Countries · 2024

DOI: 10.3855/jidc.18128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Hao Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Comorbidity, Vaccines, Inactivated. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Family Planning Committee of Pudong New Area, Shanghai Pudong New Area Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with underlying diseases do not respond adequately to vaccines. Thus, continued research on the effects of vaccination in patients with comorbidities is crucial to evaluate the necessity of vaccination in this population. This study assessed the protective effects of inactivated vaccines on the severity and prognosis of COVID-19 in patients with comorbidities. Methodology: A real-world retrospective cohort study was conducted from April 7, 2022, to June 6, 2022, at the Fudan University Pudong Medical Center. The collected data included demographic characteristics, symptoms, clinical severity, and outcomes of the COVID-19 patients.

Results

A total of 3,996 indigenous confirmed cases and asymptomatic infections with the Omicron variant were enrolled. Of these, 1322 (33.1%) patients had chronic comorbidities. Compared to others, COVID-19 patients with comorbidities were older, had lower vaccination rates, longer days of nucleic acid conversion and hospitalization, and a higher incidence of severe-critical illness and composite endpoint. Multivariable analyses suggested that in the comorbidity group, two-dose- (odds ratio [OR] 0.38, 95% CI 0.24–0.60; OR 0.20, 95% CI 0.08–0.51) and three-dose vaccinated patients (OR 0.26, 95% CI 0.14–0.47; OR 0.21, 95% CI 0.08–0.58) had a lower risk of aggravation and the composite endpoint; similar results were observed in the non-comorbidity group.

Conclusion

Two or more doses of inactivated vaccines could prevent deterioration and poor prognosis in Omicron-infected patients, regardless of the presence of an underlying disease. Our findings support maximizing coverage with inactivated vaccines in highly vaccinated populations, such as those in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesComorbidityVaccines, InactivatedSARS-CoV-2HumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedChinaVaccine EfficacySeverity of Illness Index

Stichwörter der Autor:innen

COVID-19comorbidityomicron variantprognosisseverityvaccination

Substanzen

COVID-19 VaccinesVaccines, Inactivated

Autor:innen und Institutionen

  • Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China.
  • Department of Health Examination, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China.
  • Department of Gastroenterology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China .
  • Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China.

Förderung

  • Health and Family Planning Committee of Pudong New Area
  • Shanghai Pudong New Area Health Commission

Zitieren

APA

Zhang, H., Yan, H. F., Xiong, W. J., & Gao, L. L. (2024). Real-world effectiveness of inactivated vaccine on COVID-19 patients with comorbidities. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.18128

Vancouver

Zhang H, Yan HF, Xiong WJ, Gao LL. Real-world effectiveness of inactivated vaccine on COVID-19 patients with comorbidities. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.18128

BibTeX
@article{Zhang2024,
  author = {Zhang, Hao and Yan, Hua-Fang and Xiong, Wu-Jun and Gao, Li-Li},
  title = {Real-world effectiveness of inactivated vaccine on COVID-19 patients with comorbidities},
  journal = {The Journal of Infection in Developing Countries},
  year = {2024},
  doi = {10.3855/jidc.18128}
}
Kostenlos starten →